CN103393701A - Pharmaceutical composition containing tropisetron hydrochloride and dexamethasone sodium phosphate - Google Patents
Pharmaceutical composition containing tropisetron hydrochloride and dexamethasone sodium phosphate Download PDFInfo
- Publication number
- CN103393701A CN103393701A CN2013103326179A CN201310332617A CN103393701A CN 103393701 A CN103393701 A CN 103393701A CN 2013103326179 A CN2013103326179 A CN 2013103326179A CN 201310332617 A CN201310332617 A CN 201310332617A CN 103393701 A CN103393701 A CN 103393701A
- Authority
- CN
- China
- Prior art keywords
- injection
- navoban
- soz
- sodium phosphate
- dexamethasone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a pharmaceutical composition containing containing tropisetron hydrochloride and dexamethasone sodium phosphate, and particularly relates to a combined application package containing a tropisetron hydrochloride injection and a dexamethasone sodium phosphate injection. When the combined application package is in use, the tropisetron hydrochloride injection and the dexamethasone sodium phosphate injection are co-dissolved in normal saline, a Ringer's solution, 5% glucose injection, a fructose solution and the like for intravenous infusion, so that a curative effect of stopping vomit can be increased.
Description
Technical field
The present invention relates to the pharmaceutical composition of a kind of hydrochloric tropisetron and dexamethasone sodium phosphate, be specifically related to a kind of medicinal applied in any combination packaging compositions that is formed by Navoban (Soz) injection and Decameth, belong to medical technical field.
Background technology
Former and the central nervous system's 5-hydroxy tryptamine 3(5-HT3 of a kind of peripheral nervous of Navoban (Soz)) efficient, the high selectivity competition antagonist of receptor.Cucumber comprises that some chemotherapeutic can excite the class pheochromocyte of internal organs mucosa to discharge 5-hydroxy tryptamine, thereby brings out the vomiting reflex that the companion feels sick.Navoban (Soz) mainly suppresses vomiting reflex by optionally blocking the former presynaptic 5-HT3 receptor of peripheral nervous, in addition, its antiemetic effect also may be relevant by vagal stimulation that the direct blocking-up to maincenter 5-HT3 receptor suppresses area postrema with it.
Navoban (Soz) Metabolism of Normal person's the elimination half-life (β phase) is about 7～10 hours, and in the bad person of metabolism, this value may extend to 45 hours.The CLTB of this product is about 1 liter/min of clock, wherein through what kidney was removed, is about 10%.In the bad patient of metabolism, although the constant rate of removing through kidney, CLTB is reduced to 0.1～0.2 liter/min of clock.This reduction can cause eliminating approximately 4～5 times of Increased Plasma Half-lifes, the AUC value improves 5～7 times, and Cmax and distribution volume and homergy person are without marked difference.In the bad person of metabolism, the medicine prototype ratio of through urine, discharging is large than the Metabolism of Normal person.
Navoban (Soz) is used for prevention and treats the nausea and vomiting that cancer chemotherapy causes.
Dexamethasone sodium phosphate is Aeroseb-Dex.Have antiinflammatory, antiallergic, rheumatism, immunosuppressive action, its mechanism of action is: (1) antiinflammatory action: alleviate and prevent from organizing reaction to inflammation, thus the performance that reduces inflammation.Can the inflammation-inhibiting cell, comprise macrophage and leukocyte in the gathering of inflammation part, and suppress the synthetic of the release of phagocytosis, lysosomal enzyme and inflammation chemistry mediator and discharge.(2) immunosuppressive action: comprise and prevent or suppress cell-mediated immunoreation, the anaphylaxis of retardance, reduce T lymphocyte, mononuclear cell, bite the number of acid cell, reduce the binding ability of immunoglobulin and cell surface receptor, and suppress the synthetic of interleukin and discharge, thereby reduce the T lymphocyte to lymphoblastic transformation, and alleviate that feelings are former sends out expansion immunoreactive.Dexamethasone sodium phosphate also reduces immunity and checks thing by basement membrane, and can reduce the concentration of complement component and immunoglobulin.
Dexamethasone sodium phosphate is mainly used in anaphylaxis and autoimmune inflammation disease.Multiplex in connective tissue disease, activeness rheumatism, rheumatoid arthritis, lupus erythematosus, serious bronchial asthma, serious dermatitis, ulcerative colitis, acute leukemia etc., also be used for some severe infections and Comprehensive Treatment poisoning, malignant lymphoma.
Prior art is write in the Navoban (Soz) operation instructions: Special use during alone this product unsatisfactory curative effect, does not increase drug dose and share simultaneously dexamethasone and can improve antiemetic effect.Yet, directly use Navoban (Soz) and dexamethasone still to have multiple side effect, such as constipation, headache, giddy, dizzy, stomachache, glucocorticoid syndrome etc.
Summary of the invention
In order to overcome the series of problems that exists in prior art, the inventor has creatively found to adopt Navoban (Soz) injection and the Decameth compatibility use in conjunction by particular excipient, not only the curative effect of emesis can be improved, the defect that the side effect such as existing constipation, headache, giddy, dizzy, stomachache, glucocorticoid syndrome cause can also be overcome in prior art.Especially, have been surprisingly found that be beneficial to the side effect that reduces dexamethasone sodium phosphate and the therapeutic activity that improves Navoban (Soz) the adding of glycine in the Navoban (Soz) injection.
One of purpose of the present invention, provide the pharmaceutical composition of a kind of Navoban (Soz) and dexamethasone sodium phosphate.
One of purpose of the present invention, a kind of medicinal applied in any combination packaging compositions that consists of Navoban (Soz) injection and Decameth is provided, wherein, the Navoban (Soz) injection is sterile freeze-drying preparation or aseptic parenteral solution, and Decameth is sterile freeze-drying preparation or aseptic parenteral solution.
Applied in any combination packing provided by the invention, usage is for jointly to be dissolved in the venoclysises such as normal saline, ringer's solution, 5% glucose injection or fructose soln with Navoban (Soz) injection and Decameth.
Applied in any combination packing specification provided by the invention is that Navoban (Soz) injection 2mg or 5mg or 2ml:2mg or 5ml:5mg(are by C
17H
20N
2O
2Meter), Decameth 0.5-5ml or 1-20mg.
Navoban (Soz) injection of the present invention comprises Navoban (Soz) injection and hydrochloride for injection tropisetron, the sterile freeze-drying preparation that adds the formulated aseptic parenteral solution of appropriate adjuvant or add appropriate excipient to make for Navoban (Soz).
As one of specific embodiment, concrete component and consumption are as follows:
The present invention also provides a kind of preparation method of Navoban (Soz) injection, and concrete steps are:
(1) first add the water for injection of recipe quantity 80%, 10 ℃～20 ℃ of temperature controls in material-compound tank;
(2) add the glycine of recipe quantity, stirring and dissolving is complete;
(3) add the Navoban (Soz) of recipe quantity, stirring and dissolving is complete, and regulating pH with 1mol/L sodium hydroxide solution or 1mol/L hydrochloric acid solution is 4.5-5.5;
(4) add total amount 0.02%(g/ml) injection-use activated carbon, add residue water for injection, standardize solution, stirring and adsorbing 30 minutes;
(5) the solution coarse filtration is taken off charcoal, through 0.45 μ m cartridge filter coarse filtration, then uses 0.22 μ m microporous filter membrane aseptic filtration qualified to visible foreign matters;
(6) fill, sealing, sterilizing, obtain the Navoban (Soz) injection; Perhaps, fill, lyophilization, obtain the hydrochloride for injection tropisetron.
As the present invention's one preferred embodiment, wherein in preparation method, the lyophilized injectable powder freeze drying process is:
1. the pre-freeze phase, shelf temperature is cooled to-40 ℃ ± 2 ℃, (approximately needs 3 hours) when products temperature reaches-35 ℃ ± 2 ℃, insulation approximately 2 hours, make product freeze reality fully;
2. distil the phase, when case internal pressure value reaches 10Pa when following, it is-4 ℃ ± 2 ℃ that the flaggy temperature is set, and it is 30Pa that dried case vacuum is set, and slowly heats up for flaggy, and product starts distillation (the plate temperature rises to-4 ℃ ± 2 ℃ by-40 ℃ ± 2 ℃) under vacuum condition.Shelf temperature rises to-4 ℃ ± 2 ℃, and insulation is approximately 2 hours after ice crystal disappears;
3. dry period, it is 30 ℃ that the flaggy temperature is set, and flaggy continues slowly to heat up, and product carries out drying (the plate temperature rises to 30 ℃ ± 1 ℃ by-4 ℃ ± 2 ℃ and approximately needs 2 hours) under vacuum condition; Shelf temperature reaches 30 ℃ ± 1 ℃, and products temperature is warming up to approximately 20 ℃ ± 2 ℃, and insulation approximately 2～3 hours, finish lyophilizing, presses full plug.
Decameth of the present invention comprises dexamethasone sodium phosphate injection and injection freezing-drying powder-injection contg. dexamethasone.
As one of specific embodiment, concrete component and consumption are as follows:
The present invention also provides a kind of preparation method of Decameth, and concrete steps are:
(1) to the water for injection that adds recipe quantity 50% in Agitation Tank, the sodium sulfite and propylene glycol or sodium sulfite and the mannitol that add recipe quantity, stirring makes it to dissolve, the dexamethasone sodium phosphate that adds again recipe quantity, stir to make fully and dissolve, and with the hydrochloric acid solution of 0.1mol/L or the sodium hydroxide solution adjusting pH of 0.1mol/L, is 7.5-8.5, then add recipe quantity 0.05%(g/ml) moistening medicinal charcoal, benefit adds to the full amount of water for injection, and stirs filtering decarbonization 30 minutes;
(2) with the microporous filter membrane fine straining of 0.22 μ m, fill, seal, and is sterilizing, obtains dexamethasone sodium phosphate injection; Perhaps, with the microporous filter membrane fine straining of 0.22 μ m, fill, lyophilization, obtain the injection freezing-drying powder-injection contg. dexamethasone.
The present invention also provides the applied in any combination of a kind of Navoban (Soz) injection and Decameth to be packaged in the nausea and vomiting that preparation treatment cancer chemotherapy causes, postoperatively feels sick, the application in vomiting etc.Dexamethasone sodium phosphate can improve the antiemetic effect of Navoban (Soz) when not increasing drug dose.
The specific embodiment
Embodiment 1The preparation of hydrochloride for injection tropisetron lyophilized injectable powder
Prescription:
Preparation process:
(1) first add 2800ml water for injection, 10 ℃～20 ℃ of temperature controls in container;
(2) add the 105g glycine, stirring and dissolving is complete;
(3) add Navoban (Soz) 7g(by C
17H
20N
2O
2Meter), stirring and dissolving is complete, and regulating pH with 1mol/L sodium hydroxide solution or 1mol/L hydrochloric acid solution is 4.9;
(4) add the 0.7g injection-use activated carbon, add residue water for injection, be settled to 3500ml, stirring and adsorbing 30 minutes;
(5) the solution coarse filtration is taken off charcoal, through 0.45 μ m cartridge filter coarse filtration, then uses 0.22 μ m microporous filter membrane aseptic filtration qualified to visible foreign matters;
(6) fill.
(7) lyophilization
1. the pre-freeze phase, shelf temperature is cooled to-40 ℃ ± 2 ℃, (approximately needs 3 hours) when products temperature reaches-35 ℃ ± 2 ℃, insulation approximately 2 hours, make product freeze reality fully;
2. distil the phase, when case internal pressure value reaches 10Pa when following, it is-4 ℃ ± 2 ℃ that the flaggy temperature is set, and it is 30Pa that dried case vacuum is set, and slowly heats up for flaggy, and product starts distillation (the plate temperature rises to-4 ℃ ± 2 ℃ by-40 ℃ ± 2 ℃) under vacuum condition.Shelf temperature rises to-4 ℃ ± 2 ℃, and insulation is approximately 2 hours after ice crystal disappears;
3. dry period, it is 30 ℃ that the flaggy temperature is set, and flaggy continues slowly to heat up, and product carries out drying (the plate temperature rises to 30 ℃ ± 1 ℃ by-4 ℃ ± 2 ℃ and approximately needs 2 hours) under vacuum condition; Shelf temperature reaches 30 ℃ ± 1 ℃, and products temperature is warming up to approximately 20 ℃ ± 2 ℃, and insulation approximately 2～3 hours, finish lyophilizing, presses full plug.
(8) roll lid, obtain.
Embodiment 2The preparation of Navoban (Soz) injection
Prescription:
Preparation process:
(1) first add 5600ml water for injection, 10 ℃～20 ℃ of temperature controls in container;
(2) add Navoban (Soz) 7g(by C
17H
20N
2O
2Meter), stirring and dissolving is complete, and regulating pH with 1mol/L sodium hydroxide solution or 1mol/L hydrochloric acid solution is 5.0;
(4) add the 1.4g injection-use activated carbon, add residue water for injection, be settled to 7000ml, stirring and adsorbing 30 minutes;
(5) the solution coarse filtration is taken off charcoal, through 0.45 μ m cartridge filter coarse filtration, then uses 0.22 μ m microporous filter membrane aseptic filtration qualified to visible foreign matters;
(6) fill, sealing, sterilizing.
Embodiment 3The preparation of dexamethasone sodium phosphate injection
Prescription:
Preparation process:
(1) add 500ml water for injection in beaker, add 2g sodium sulfite and 300ml propylene glycol, stirring makes it to dissolve, adding the 1g dexamethasone sodium phosphate again, stir to make fully and dissolve, is 7.8 with the hydrochloric acid solution of 0.1mol/L or the sodium hydroxide solution adjusting pH of 0.1mol/L, then add the moistening medicinal charcoal of 0.5g, add water for injection to 1000ml, stirred filtering decarbonization 30 minutes; With the microporous filter membrane fine straining of 0.22 μ m, fill, 1ml/ props up, sealing; 121 ℃ of pressure sterilizings 15 minutes, spraying cooling, offer for sale fast, naturally cools to room temperature.
(2) add 500ml water for injection in beaker, add 2g sodium sulfite and 300ml propylene glycol, stirring makes it to dissolve, adding the 2g dexamethasone sodium phosphate again, stir to make fully and dissolve, is 7.7 with the hydrochloric acid solution of 0.1mol/L or the sodium hydroxide solution adjusting pH of 0.1mol/L, then add the moistening medicinal charcoal of 0.5g, add water for injection to 1000ml, stirred filtering decarbonization 30 minutes; With the microporous filter membrane fine straining of 0.22 μ m, fill, 1ml/ props up, sealing; 121 ℃ of pressure sterilizings 15 minutes, spraying cooling, offer for sale fast, naturally cools to room temperature.
(3) add 500ml water for injection in beaker, add 2g sodium sulfite and 300ml propylene glycol, stirring makes it to dissolve, adding the 5g dexamethasone sodium phosphate again, stir to make fully and dissolve, is 7.6 with the hydrochloric acid solution of 0.1mol/L or the sodium hydroxide solution adjusting pH of 0.1mol/L, then add the moistening medicinal charcoal of 0.5g, add water for injection to 1000ml, stirred filtering decarbonization 30 minutes; With the microporous filter membrane fine straining of 0.22 μ m, fill, 1ml/ props up, sealing; 121 ℃ of pressure sterilizings 15 minutes, spraying cooling, offer for sale fast, naturally cools to room temperature.
Embodiment 4The preparation of injection freezing-drying powder-injection contg. dexamethasone
Prescription:
Preparation process:
(1) add 500ml water for injection in beaker, add 2g sodium sulfite and 50g mannitol, stirring makes it to dissolve, adding the 1g dexamethasone sodium phosphate again, stir to make fully and dissolve, is 7.7 with the hydrochloric acid solution of 0.1mol/L or the sodium hydroxide solution adjusting pH of 0.1mol/L, then add the moistening medicinal charcoal of 0.5g, add water for injection to 1000ml, stirred filtering decarbonization 30 minutes; With the microporous filter membrane fine straining of 0.22 μ m, fill, 1ml/ bottle, lyophilization, obtain the injection freezing-drying powder-injection contg. dexamethasone.
(2) add 500ml water for injection in beaker, add 2g sodium sulfite and 50g mannitol, stirring makes it to dissolve, adding the 2g dexamethasone sodium phosphate again, stir to make fully and dissolve, is 7.9 with the hydrochloric acid solution of 0.1mol/L or the sodium hydroxide solution adjusting pH of 0.1mol/L, then add the moistening medicinal charcoal of 0.5g, add water for injection to 1000ml, stirred filtering decarbonization 30 minutes; With the microporous filter membrane fine straining of 0.22 μ m, fill, 1ml/ bottle, lyophilization, obtain the injection freezing-drying powder-injection contg. dexamethasone.
(3) add 500ml water for injection in beaker, add 2g sodium sulfite and 50g mannitol, stirring makes it to dissolve, adding the 5g dexamethasone sodium phosphate again, stir to make fully and dissolve, is 7.8 with the hydrochloric acid solution of 0.1mol/L or the sodium hydroxide solution adjusting pH of 0.1mol/L, then add the moistening medicinal charcoal of 0.5g, add water for injection to 1000ml, stirred filtering decarbonization 30 minutes; With the microporous filter membrane fine straining of 0.22 μ m, fill, 1ml/ bottle, lyophilization, obtain the injection freezing-drying powder-injection contg. dexamethasone.
Embodiment 5The preparation of assembly packaging medicine
Combination 1: hydrochloride for injection tropisetron freeze-dried powder 2mg and dexamethasone sodium phosphate injection 1ml:1mg.
Combination 2: hydrochloride for injection tropisetron freeze-dried powder 2mg and dexamethasone sodium phosphate injection 1ml:2mg.
Combination 3: hydrochloride for injection tropisetron freeze-dried powder 2mg and dexamethasone sodium phosphate injection 1ml:5mg.
Combination 4: hydrochloride for injection tropisetron freeze-dried powder 5mg and dexamethasone sodium phosphate injection 1ml:1mg.
Combination 5: hydrochloride for injection tropisetron freeze-dried powder 5mg and dexamethasone sodium phosphate injection 1ml:2mg.
Combination 6: hydrochloride for injection tropisetron freeze-dried powder 5mg and dexamethasone sodium phosphate injection 1ml:5mg.
Combination 7: Navoban (Soz) injection 2ml:2mg and dexamethasone sodium phosphate injection 1ml:1mg.
Combination 8: Navoban (Soz) injection 2ml:2mg and dexamethasone sodium phosphate injection 1ml:2mg.
Combination 9: Navoban (Soz) injection 2ml:2mg and dexamethasone sodium phosphate injection 1ml:5mg.
Combination 10: Navoban (Soz) injection 5ml:5mg and dexamethasone sodium phosphate injection 1ml:1mg.
Combination 11: Navoban (Soz) injection 5ml:5mg and dexamethasone sodium phosphate injection 1ml:2mg.
Combination 12: Navoban (Soz) injection 5ml:5mg and dexamethasone sodium phosphate injection 1ml:5mg.
Combination 13: hydrochloride for injection tropisetron freeze-dried powder 2mg and injection freezing-drying powder-injection contg. dexamethasone 1mg.
Combination 14: hydrochloride for injection tropisetron freeze-dried powder 2mg and injection freezing-drying powder-injection contg. dexamethasone 2mg.
Combination 15: hydrochloride for injection tropisetron freeze-dried powder 2mg and injection freezing-drying powder-injection contg. dexamethasone 5mg.
Combination 16: hydrochloride for injection tropisetron freeze-dried powder 5mg and injection freezing-drying powder-injection contg. dexamethasone 1mg.
Combination 17: hydrochloride for injection tropisetron freeze-dried powder 5mg and injection freezing-drying powder-injection contg. dexamethasone 2mg.
Combination 18: hydrochloride for injection tropisetron freeze-dried powder 5mg and injection freezing-drying powder-injection contg. dexamethasone 5mg.
Combination 19: Navoban (Soz) injection 2ml:2mg and injection freezing-drying powder-injection contg. dexamethasone 1mg.
Combination 20: Navoban (Soz) injection 2ml:2mg and injection freezing-drying powder-injection contg. dexamethasone 2mg.
Combination 21: Navoban (Soz) injection 2ml:2mg and injection freezing-drying powder-injection contg. dexamethasone 5mg.
Combination 22: Navoban (Soz) injection 5ml:5mg and injection freezing-drying powder-injection contg. dexamethasone 1mg.
Combination 23: Navoban (Soz) injection 5ml:5mg and injection freezing-drying powder-injection contg. dexamethasone 2mg.
Combination 24: Navoban (Soz) injection 5ml:5mg and injection freezing-drying powder-injection contg. dexamethasone 5mg.
Test example 1 pharmacology irritant test
Get 32 of the New Zealand Journal of Health Physical Education does of body weight 2.0-2.5kg, be divided at random eight groups.New zealand rabbit is placed in holder, every group of medicine of injecting respectively the 1st, 6,7,12,13,18,19,24 combinations in the embodiment of the present invention 5, every new zealand rabbit injection 4ml, during injection and after injection, note to observe injection site and have or not redness, hyperemia, the stimulation such as hemorrhage and downright bad., with sacrifice of animal, drawn materials in injection site after 24 hours in the last administration, carry out histopathologic examination.
Result of the test:
Perusal: eight groups the significantly irritant reaction such as red and swollen, congested, downright bad all occurs.
Pathological examination: eight groups of skin histology structures are normal, and epidermis is without thickening, and subcutaneous tissue has no the morphological changes such as hyperemia, edema, has no the changes such as inflammatory cell infiltration.
Conclusion: assembly packaging product of the present invention with respect to the effect of one-component application of stimulus without obvious increase.
Test example 2 antiemetic effect tests
Choose nausea and vomiting patient 120 examples that certain hospital's cancer chemotherapy causes, be divided at random six groups, every group of 20 examples:
The hydrochloride for injection tropisetron freeze-dried powder 2mg+5% glucose 250ml of first group of venoclysis embodiment 1, once a day;
The Navoban (Soz) injection 2ml:2mg+5% glucose 250ml of second group of venoclysis embodiment 2, once a day;
Make up 8 Navoban (Soz) injection 2ml:2mg+ dexamethasone sodium phosphate injection 1ml:2mg+5% glucose 250ml in the 3rd group of venoclysis embodiment 5, once a day;
Make up 20 Navoban (Soz) injection 2ml:2mg+ injection freezing-drying powder-injection contg. dexamethasone 2mg+5% glucose 250ml in the 4th group of venoclysis embodiment 5, once a day.
Make up 2 hydrochloride for injection tropisetron freeze-dried powder 2mg+ dexamethasone sodium phosphate injection 1ml:2mg+5% glucose 250ml in the 5th group of venoclysis embodiment 5, once a day;
Make up 14 hydrochloride for injection tropisetron freeze-dried powder 2mg+ injection freezing-drying powder-injection contg. dexamethasone 2mg+5% glucose 250ml in the 6th group of venoclysis embodiment 5, once a day;
Continuous use 6 days.Efficacy result such as following table:
Six groups of patients' of table 1 clinical effectiveness
| Group | Number of cases | Produce effects | Effectively | Invalid | Total effective rate | Untoward reaction |
| First group | 20 | 9 | 5 | 6 | 70% | 12 |
| Second group | 20 | 10 | 6 | 4 | 80% | 14 |
| The 3rd group | 20 | 16 | 3 | 1 | 95% | 8 |
| The 4th group | 20 | 17 | 1 | 2 | 90% | 7 |
| The 5th group | 20 | 17 | 3 | 0 | 100% | 5 |
| The 6th group | 20 | 18 | 2 | 0 | 100% | 4 |
Six groups of patients' of table 2 untoward reaction contrast
Can find out by above result, the 3rd group to the 6th group of six groups of patients' total effective rate is apparently higher than to first group and second group; Illustrate that assembly packaging Navoban (Soz) injection of the present invention and Decameth share better than independent use Navoban (Soz) injection antiemetic effect, the less adverse effect that side effect causes.
In addition, adopt the 5th group of glycine and the effect of the 6th group also will, due to the 3rd and four group, show the unforeseeable technique effect of the present invention.
Claims (3)
1. pharmaceutical composition that comprises Navoban (Soz) injection and Decameth, it is characterized in that the Navoban (Soz) injection comprises Navoban (Soz) injection and hydrochloride for injection tropisetron lyophilized injectable powder, the sterile freeze-drying preparation that adds the formulated aseptic parenteral solution of appropriate adjuvant or add appropriate excipient to make for Navoban (Soz); Decameth is sterile freeze-drying preparation or the aseptic parenteral solution that contains dexamethasone sodium phosphate.
2. pharmaceutical composition according to claim 1, the specification that it is characterized in that the Navoban (Soz) injection are that 2mg or 5mg or 2ml:2mg or 5ml:5mg(are by C
17H
20N
2O
2Meter); The Decameth specification is 0.5-5ml or 1-20mg.
3. pharmaceutical composition according to claim 1, is characterized in that this pharmaceutical composition can pack for applied in any combination.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310332617.9A CN103393701B (en) | 2013-08-02 | 2013-08-02 | Pharmaceutical composition containing tropisetron hydrochloride and dexamethasone sodium phosphate |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310332617.9A CN103393701B (en) | 2013-08-02 | 2013-08-02 | Pharmaceutical composition containing tropisetron hydrochloride and dexamethasone sodium phosphate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103393701A true CN103393701A (en) | 2013-11-20 |
| CN103393701B CN103393701B (en) | 2014-07-02 |
Family
ID=49557556
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310332617.9A Expired - Fee Related CN103393701B (en) | 2013-08-02 | 2013-08-02 | Pharmaceutical composition containing tropisetron hydrochloride and dexamethasone sodium phosphate |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103393701B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012091357A2 (en) * | 2010-12-27 | 2012-07-05 | Samyang Biopharmaceuticals Corporation | Composition for prevention of nausea or vomiting |
-
2013
- 2013-08-02 CN CN201310332617.9A patent/CN103393701B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012091357A2 (en) * | 2010-12-27 | 2012-07-05 | Samyang Biopharmaceuticals Corporation | Composition for prevention of nausea or vomiting |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103393701B (en) | 2014-07-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103393693B (en) | Pharmaceutical composition of ondansetron hydrochloride and dexamethasone | |
| CN101961311B (en) | 5alpha-androstane (alkyl)-3beta,5,6beta-triol injection and preparation method thereof | |
| CN101095659A (en) | Liposome combined medicine and method for preparing the same | |
| US20040101573A1 (en) | Injectable composition for cancer treatment | |
| CN101623254A (en) | Gastrodin injection and preparation method thereof | |
| CN103393701B (en) | Pharmaceutical composition containing tropisetron hydrochloride and dexamethasone sodium phosphate | |
| CN103393694B (en) | Pharmaceutical composition containing tropisetron hydrochloride and dexamethasone acetate | |
| CN109966290A (en) | Application and its pharmaceutical composition of the CID1067700 in the drug of preparation prevention and/or treatment cranial vascular disease | |
| CN101264089A (en) | Fusidate sodium composition and preparation of its freeze-drying preparations | |
| US11419905B2 (en) | Bacteroides ovatus for relieving endotoxin infection and application thereof | |
| CN106668100A (en) | Application of eight-component medicine in preparing drug for treating meningitis | |
| CN1314406C (en) | Application of montmorillonite in pharmacy | |
| CN103432086B (en) | Pemetrexed disodium freeze-dried powder injection for injection and preparation method thereof | |
| CN101049312B (en) | Composition of medication, preparation method and application | |
| CN102441160B (en) | Thymosin alpha1 medicinal composition and preparation method thereof | |
| CN1626081A (en) | Ropivacaine freeze-dried powder and injection preparation in use for injection and preparation method | |
| CN1657100B (en) | Nano-class preparation for selective target stomach cancer-and lymph system and its preparation method | |
| CN104857019A (en) | Novel oral rehydration salts solution and preparation method and use thereof | |
| CN104645334B (en) | N acetylcysteine activated carbon composites and its preparation method and application | |
| CN103385883A (en) | Pharmaceutical composition containing tropisetron hydrochloride and fructose | |
| CN104352520B (en) | Calf spleen extract and the purposes in the treatment of primary immune thrombocytopenia | |
| CN102552180B (en) | Clindamycin phosphate composition liensinine freeze-dried powder and preparation method thereof | |
| CN111467350B (en) | Medicine for treating mastitis and preparation method thereof | |
| CN107879961A (en) | A kind of composition for treating liver fibrosis | |
| CN117752681A (en) | Improvement of compound clove basil preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140702 Termination date: 20170802 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |